| chronic pain (diagnosis)
Lyrica vs Mitigo
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Lyrica vs Mitigo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMitigo has a higher rate of injection site reactions vs Lyrica based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mitigo but not Lyrica, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lyrica
Mitigo
At A Glance
Oral
2-3 times daily
alpha2-delta calcium channel ligand
Epidural/intrathecal infusion
Daily (continuous infusion)
Opioid agonist
Indications
- Peripheral Nervous System Diseases
- Epilepsy
- Fibromyalgia
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
Peripheral Nervous System Diseases Begin at 150 mg/day in 3 divided doses; may increase to max 300 mg/day within 1 week; oral.
chronic pain (diagnosis) PHN: begin at 150 mg/day (75 mg BID or 50 mg TID), max up to 600 mg/day. Spinal cord injury neuropathic pain: begin at 150 mg/day (75 mg BID), max 600 mg/day; oral.
Epilepsy Adults: begin at 150 mg/day in 2 or 3 divided doses, max 600 mg/day. Pediatric >=30 kg: begin 2.5 mg/kg/day, max 10 mg/kg/day. Pediatric <30 kg: begin 3.5 mg/kg/day, max 14 mg/kg/day; oral.
Fibromyalgia Begin at 150 mg/day (75 mg BID); may increase to 300 mg/day within 1 week; max 450 mg/day; oral.
chronic pain (diagnosis) - Epidural Initial 3.5-7.5 mg/day (opioid-naive) or 4.5-10 mg/day (opioid-tolerant) via continuous epidural infusion; dose requirements may increase to 20-30 mg/day; titrate individually to adequate analgesia.
chronic pain (diagnosis) - Intrathecal Initial 0.2-1 mg/day (opioid-naive) or 1-10 mg/day (opioid-tolerant) via lumbar intrathecal infusion; intrathecal dose is typically 1/10 of epidural dose; doses above 20 mg/day should be used with caution.
Contraindications
- Known hypersensitivity to pregabalin or any of its components
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
- Concurrent use of MAOIs or use within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
- Infection at the neuraxial injection or microinfusion site
- Concomitant anticoagulant therapy (neuraxial administration)
- Uncontrolled bleeding diathesis (neuraxial administration)
- Any concomitant therapy or medical condition rendering epidural or intrathecal administration especially hazardous
Adverse Reactions
Most common (>=5%) Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal
Serious Angioedema, hypersensitivity, suicidal behavior and ideation, respiratory depression, peripheral edema, weight gain, tumorigenic potential, ophthalmological effects, creatine kinase elevations, decreased platelet count, PR interval prolongation
Postmarketing Headache, nausea, diarrhea, gynecomastia, breast enlargement, bullous pemphigoid, life-threatening respiratory depression with opioids or CNS depressants
Most common Nausea, vomiting, constipation, pruritus, urinary retention, dizziness, headache, myoclonus, anxiety, confusion
Serious Respiratory depression, myoclonus, inflammatory masses, seizures, severe hypotension, adrenal insufficiency, serotonin syndrome, anaphylaxis
Postmarketing Androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues, reducing calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and exerting antiseizure effects; it is a structural GABA analogue but does not act directly on GABA receptors, sodium channels, or opiate receptors.
Morphine is a full opioid agonist selective for the mu-opioid receptor that produces analgesia through CNS opioid receptors in the brain and spinal cord; it also causes respiratory depression by direct action on brain stem respiratory centers and reduces GI motility through smooth muscle effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lyrica
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
Mitigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lyrica
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Mitigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lyrica
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Mitigo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lyrica.
No savings programs available for Mitigo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LyricaView full Lyrica profile
MitigoView full Mitigo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.